Sungkyunkwan University

About: Sungkyunkwan University is a education organization based out in Seoul, South Korea. It is known for research contribution in the topics: Graphene & Thin film. The organization has 28229 authors who have published 56428 publications receiving 1352733 citations. The organization is also known as: 성균관대학교.

Anti‐Solvent Derived Non‐Stacked Reduced Graphene Oxide for High Performance Supercapacitors

Abstract: An anti-solvent for graphene oxide (GO), hexane, is introduced to increase the surface area and the pore volume of the non-stacked GO/reduced GO 3D structure and allows the formation of a highly crumpled non-stacked GO powder, which clearly shows ideal supercapacitor behavior.

Wireless Powered Communication Networks: Research Directions and Technological Approaches

Abstract: Current wireless and cellular networks are destined to undergo a significant change in the transition to the next generation of network technology. The so called wireless powered communication network (WPCN) has been recently emerging as a promising candidate for achieving the target performance of future networks. According to this paradigm, nodes in a WPCN can be equipped with hardware capable of harvesting energy from wireless signals, that is, their battery can be ubiquitously replenished without physical connections. Recent technological advances in the field of wireless power harvesting and transfer are providing strong evidence of the feasibility of this vision, especially for low-power devices. The future deployment of WPCN is more and more concretely foreseen. The aim of this article is therefore to provide a comprehensive review of the basics and backgrounds of WPCN, current major developments, and open research issues. In particular, we first give an overview of WPCN and its structure. We then present three major advanced approaches whose adoption could increase the performance of future WPCN: backscatter communications with energy harvesting; duty-cycle based energy management; and transceiver design for self-sustainable communications. We discuss implementation perspectives and tools for WPCN. Finally, we outline open research problems for WPCN.

What is the future of PEGylated therapies

Abstract: The tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic (PK) profiles of therapeutic agents and has been applied in the clinic for over 25 years. Over 10 PEGylated therapeutics have entered the clinic since the early 1990 s, and new PEGylated agents continue to expand clinical pipelines and drug patent life. PEGylation is the most established half-life extension technology in the clinic with proven safety in humans for over two decades. Still, it is one of the most evolving and emerging technologies that will be applied for the next two decades.